<?xml version="1.0" encoding="UTF-8"?>
<p>Over the last few months, the SARS-CoV2 pandemic has had an impact on chronic therapies in patients with rare disease, such as alpha-1 antitrypsin deficiency (AATD). Augmentation therapy with exogenous AAT is the only specific therapy for the lung disease associated with AATD. The biochemical and clinical efficacy of AAT therapy has been well established in numerous studies–a dose of 60 mg/kg per week (
 <xref rid="B4" ref-type="bibr">Chapman et al., 2009</xref>; 
 <xref rid="B7" ref-type="bibr">McElvaney et al., 2017</xref>).
</p>
